Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
Simara P, Peterkova M, Stejskal S, Potesilova M, Koutna I, Racil Z, Razga F, Jurcek T, Dvorakova D, Mayer J. Simara P, et al. Among authors: dvorakova d. Leuk Lymphoma. 2012 Aug;53(8):1627-9. doi: 10.3109/10428194.2012.656104. Epub 2012 Mar 1. Leuk Lymphoma. 2012. PMID: 22233112 No abstract available.
Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.
Razga F, Jurcek T, Jeziskova I, Zackova D, Dvorakova D, Borsky M, Mayer J, Racil Z. Razga F, et al. Among authors: dvorakova d. Mol Diagn Ther. 2012 Jun 1;16(3):163-6. doi: 10.2165/11632420-000000000-00000. Mol Diagn Ther. 2012. PMID: 22489663
The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.
Malcikova J, Razga F, Jurcek T, Dvorakova D, Zackova D, Toskova M, Sebejova L, Smardova J, Oltova A, Vankova G, Jurackova L, Trbusek M, Pospisilova S, Mayer J, Racil Z. Malcikova J, et al. Among authors: dvorakova d. Leuk Lymphoma. 2013 Sep;54(9):2083-7. doi: 10.3109/10428194.2012.762649. Epub 2013 Feb 1. Leuk Lymphoma. 2013. PMID: 23289360 No abstract available.
Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Zackova D, Klamova H, Muzik J, Cmunt E, Racil Z, Machova Polakova K, Dvorakova D, Jurcek T, Razga F, Cetkovsky P, Dusek L, Mayer J. Zackova D, et al. Among authors: dvorakova d. Leuk Lymphoma. 2013 Oct;54(10):2310-3. doi: 10.3109/10428194.2013.772173. Epub 2013 Feb 28. Leuk Lymphoma. 2013. PMID: 23373966 No abstract available.
Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.
Culen M, Borsky M, Nemethova V, Razga F, Smejkal J, Jurcek T, Dvorakova D, Zackova D, Weinbergerova B, Semerad L, Sadovnik I, Eisenwort G, Herrmann H, Valent P, Mayer J, Racil Z. Culen M, et al. Among authors: dvorakova d. Oncotarget. 2016 May 31;7(22):33016-24. doi: 10.18632/oncotarget.9108. Oncotarget. 2016. PMID: 27145281 Free PMC article.
121 results